Patient P-03198
Therapy response
Stable
Tolerance
Deteriorating
GI state
Favorable
Inflammatory state
Deteriorating
Nutritional resilience
Favorable
Discontinuation risk
15%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 ONX-7 started — Baseline state S11
- Day 14 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 18 GI-04 recommended — GI Support Protocol GI-04
- Day 19 Patient declined — Not now
What changed?
Trajectory began diverging from predicted response on Day 14.
Primary contributors, last 14 days
- Inflammatory activity+5
- Toxicity+5
- Nutritional resilience-2
- Treatment adherence+2
What helped?
- GI Support Protocol GI-04Day 18Declined by patient
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Energy level
Daily log5.4/10
worsening · -0.3 vs previous 14 d
Stress level
Daily log4.6/10
worsening · +0.4 vs previous 14 d
Pessimism score
Daily log4.6/10
worsening · +0.5 vs previous 14 d
Sleep quality
Wearable47/100
worsening · -2.2 vs previous 14 d
Libido
Daily log5/10
worsening · -0.3 vs previous 14 d
HRV
Wearable38.2 ms
worsening · -3.4 vs previous 14 d
Toxicity
Blood20.1/100
worsening · +4.2 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 63 from the failing basin, 29 from restoration.
Would help
- No untried action with strong evidence. Compose one from primitives.
- More proteinGI -4 next day on high-intake days · n 15
Would not help
- AD-05 Adherence Supportonly 29% improved among 14 similar
- Keep fat lowGI +3.4 next day on high-intake days · n 18
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Protein-4supporter · 95%
- Dietary fat load+3.4detractor · 95%
- Lactose+1.7no signal · 52%
- Alcohol+1no signal · 21%
- Histamine load+0.8no signal · 22%
- Caffeine-0.6no signal · 19%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Butyrate / short-chain fatty acid production ↓35
- MicrobiomeButyrate capacity 30/100
- Drug metabolism and exposure ↑35
- DNADPYD *2A → slower clearance
- Mucosal barrier integrity ↓30
- MicrobiomeAkkermansia low → thinner mucus layer
- Autonomic recovery ↑25
- WearableResting HR 75 bpm
DNA
Fictional pharmacogenomic panel
- DPYD *2A heterozygousSlower drug clearance
- CYP2D6 Rapid metabolizerExpected exposure
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 2.7 · butyrate capacity 30/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 34 ms
- Sleep
- 7.3 h
- Steps
- 6,471
- Resting HR
- 75 bpm
Daily log: GI score 25, nutritional resilience 60, adherence 99.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-03204 | 41% | S16 | AD-05 | improved | 48 |
| P-03105 | 38% | S12 | AD-05 | no change | 60 |
| P-03111 | 36% | S07 | AD-05 | no change | 48 |
| P-03482 | 35% | S05 | AD-05 | no change | 67 |
| P-03369 | 34% | S18 | AD-05 | no change | 37 |
| P-03424 | 34% | S12 | AD-05 | improved | 41 |
| P-03351 | 33% | S07 | AD-05 | no change | 51 |
| P-03380 | 33% | S16 | AD-05 | improved | 34 |
| P-03129 | 32% | S18 | AD-05 | no change | 32 |
| P-03034 | 31% | S14 | AD-05 | no change | 30 |
| P-03187 | 31% | S12 | AD-05 | no change | 80 |
| P-03441 | 30% | S19 | AD-05 | improved | 37 |